Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

    Janet DuBois, Suzanne Bruce, Daniel Stewart, Steven Kempers, Christy Harutunian, Terry Boodhoo, Amy Weitzenfeld, Joan-En Chang-Lin
    TLDR Setipiprant did not significantly improve hair growth in men with hair loss.
    The study evaluated the efficacy and safety of setipiprant, a CRTH2 antagonist, for treating androgenetic alopecia (AGA) in 169 men over 24 weeks. Results showed no significant improvement in hair growth with setipiprant compared to placebo, although it was well tolerated. Finasteride, used as an unblinded reference, showed greater numerical improvements in hair count but was not formally compared. The study concluded that setipiprant did not significantly enhance hair growth in men with AGA.
    Discuss this study in the Community →

    Research cited in this study

    17 / 17 results

    Related Community Posts Join

    6 / 40 results

    Related Research

    1 / 1 results